Literature DB >> 11034247

Taurolidine inhibits tumor cell growth in vitro and in vivo.

M McCourt1, J H Wang, S Sookhai, H P Redmond.   

Abstract

BACKGROUND: Taurolidine, a derivative of the amino acid taurine, exhibits antiendotoxin, antibacterial, and antiadherence activity. We hypothesized that Taurolidine may inhibit tumor cell growth, both in an in vitro and in vivo setting. Our aim was to examine the effect of Taurolidine on the growth of a rat metastatic colorectal tumor cell line (DHD/K12/TRb) in vitro and in vivo.
METHODS: In the in vitro experiments, DHD/K12/TRb cells were incubated with 5, 10, 15, 25, microg/ml of Taurolidine. Cells incubated in culture medium alone were used as controls. Cell proliferation, cell viability, cell death, and cell apoptosis were measured using commercially available techniques. In the in vivo experiment, BD IX rats were randomized into two groups (n = 10/group). Group A (control) underwent laparotomy and instillation of DHD/K12/TRb tumor cells intraperitoneally followed by phosphate buffered saline (PBS). Group B received Taurolidine (100 mg/kg) instead of PBS. Animals were killed after 24 days and tumor burden assessed by counting the number of tumor nodules in the peritoneal cavity.
RESULTS: Incubation of the tumor cells with Taurolidine resulted in a 4-fold decrease in proliferation rates (25+/-4% vs. 100+/-28% for controls) and a 4-fold increase in cell necrosis as demonstrated by the increase in LDH release (403+/-28% vs. 100+/-26% for controls), at a Taurolidine concentration of 25 microg/ml. A dose-dependent decrease in cell viability was also observed. In the in vivo study, local Taurolidine administration resulted in significant decreases in tumor burden (3+/-1 nodules in Group B animals vs. 649+/-101 nodules in Group A animals).
CONCLUSIONS: Taurolidine inhibits the growth of a rat metastatic colorectal tumor cell line in vitro and in vivo and thus may have potential in the prevention of peritoneal metastases.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11034247     DOI: 10.1007/s10434-000-0685-6

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  26 in total

1.  Comparative analysis of cell death induction by Taurolidine in different malignant human cancer cell lines.

Authors:  Ansgar M Chromik; Adrien Daigeler; Daniel Bulut; Annegret Flier; Christina May; Kamran Harati; Jan Roschinsky; Dominique Sülberg; Peter R Ritter; Ulrich Mittelkötter; Stephan A Hahn; Waldemar Uhl
Journal:  J Exp Clin Cancer Res       Date:  2010-03-07

2.  Effect of taurine on the proliferation and apoptosis of human hepatocellular carcinoma HepG2 cells.

Authors:  Shuo Tu; Xiali Zhang; Daya Luo; Zhuoqi Liu; Xiaohong Yang; Huifang Wan; Lehan Yu; Hua Li; Fusheng Wan
Journal:  Exp Ther Med       Date:  2015-05-07       Impact factor: 2.447

Review 3.  Taurine and inflammatory diseases.

Authors:  Janusz Marcinkiewicz; Ewa Kontny
Journal:  Amino Acids       Date:  2012-07-19       Impact factor: 3.520

4.  Influence of intraperitoneal and systemic application of taurolidine and taurolidine/heparin during laparoscopy on intraperitoneal and subcutaneous tumour growth in rats.

Authors:  C Braumann; J Ordemann; P Wildbrett; C A Jacobi
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

5.  Effects of increasing doses of a bolus injection and an intravenous long-term therapy of taurolidine on subcutaneous (metastatic) tumor growth in rats.

Authors:  Chris Braumann; Marco Schoenbeck; Charalambos Menenakos; Maik Kilian; Christoph A Jacobi
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

6.  Oral administration of the anti-proliferative substance taurolidine has no impact on dextran sulfate sodium induced colitis-associated carcinogenesis in mice.

Authors:  Ansgar Michael Chromik; Sebastian Huss; Hayssam Osseili; Adrien Daigeler; Sabine Kersting; Dominique Sülberg; Ulrich Mittelkötter; Thomas Herdegen; Waldemar Uhl; Annette M Müller
Journal:  J Carcinog       Date:  2010-04-16

7.  Taurolidine: a novel anti-neoplastic agent induces apoptosis of osteosarcoma cell lines.

Authors:  Denise K Walters; Roman Muff; Bettina Langsam; Philipp Gruber; Walter Born; Bruno Fuchs
Journal:  Invest New Drugs       Date:  2007-04-26       Impact factor: 3.850

8.  The effects of taurolidine alone and in combination with doxorubicin or carboplatin in canine osteosarcoma in vitro.

Authors:  Kevin Marley; Stuart C Helfand; Wade A Edris; John E Mata; Alix I Gitelman; Jan Medlock; Bernard Séguin
Journal:  BMC Vet Res       Date:  2013-01-18       Impact factor: 2.741

9.  Evaluation of the safety and efficacy of TRAIL and taurolidine use on human fibrosarcoma xenografts in vivo.

Authors:  Kamran Harati; Sabine Emmelmann; Björn Behr; Ole Goertz; Tobias Hirsch; Nicolai Kapalschinski; Jonas Kolbenschlag; Ingo Stricker; Andrea Tannapfel; Marcus Lehnhardt; Adrien Daigeler
Journal:  Oncol Lett       Date:  2016-01-15       Impact factor: 2.967

10.  Taurolidine reduces the tumor stimulating cytokine interleukin-1beta in patients with resectable gastrointestinal cancer: a multicentre prospective randomized trial.

Authors:  Chris Braumann; Carsten N Gutt; Johannes Scheele; Charalambos Menenakos; Wilhelm Willems; Joachim M Mueller; Christoph A Jacobi
Journal:  World J Surg Oncol       Date:  2009-03-23       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.